✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
MLN9708 is an investigational drug.
There have been 85 clinical trials for MLN9708. The most recent clinical trial was a Phase 3 trial, which was initiated on September 20th 2017.
The most common disease conditions in clinical trials are Multiple Myeloma, Neoplasms, Plasma Cell, and Lymphoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and Mayo Clinic.
There are thirty-seven US patents protecting this investigational drug and three hundred and forty-seven international patents.
Recent Clinical Trials for MLN9708
|Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis||National Cancer Institute (NCI)||Phase 1|
|Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial||National Cancer Institute (NCI)||Phase 3|
|Trial of Ixazomib for Kaposi Sarcoma||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for MLN9708
Top clinical trial sponsors for MLN9708
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MLN9708||See Plans and Pricing||Proteasome inhibition assay and methods of use||Beckman Coulter, Inc. (Brea, CA) University Health Network (Toronto, CA)||See Plans and Pricing|
|MLN9708||See Plans and Pricing||Glycolipid containing compositions for use in the treatment of tumors||Agalimmune Limited (GB)||See Plans and Pricing|
|MLN9708||See Plans and Pricing||Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor||Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)||See Plans and Pricing|
|MLN9708||See Plans and Pricing||Formylated N-heterocyclic derivatives as FGFR4 inhibitors||NOVARTIS AG (Basel, CH)||See Plans and Pricing|
|MLN9708||See Plans and Pricing||Pyrrolcarboxamide derivatives for the inhibition of ERK5||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|MLN9708||European Patent Office||EP3058086||2033-10-18||See Plans and Pricing|
|MLN9708||European Patent Office||EP3360969||2033-10-18||See Plans and Pricing|
|MLN9708||World Intellectual Property Organization (WIPO)||WO2015057402||2033-10-18||See Plans and Pricing|
|MLN9708||Australia||AU2015257496||2034-05-09||See Plans and Pricing|
|MLN9708||Canada||CA2948439||2034-05-09||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|